Furthermore, it has been reported that in cancer cells, inhibition of telomerase activity might activate a recombination-based alternative lengthening of telomeres (ALT) mechanism for telomere maintenance, which is one of the major limitations for the development of clinically useful telomerase inhibitors [6, 11, 12]. The gene discussed is GPT; the disease is cancer.